Choline alphoscerate: insights between acquired certainties and future perspectives.
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacological and clinical evidence without systematic review methodology
PubMed 40842650 · doi:10.3389/fnagi.2025.1613566
What was done
This paper is a narrative review summarizing pharmacological mechanisms and clinical evidence regarding choline alphoscerate (a cholinergic precursor) in mild cognitive impairment (MCI), Alzheimer's disease, and vascular cognitive impairment. The review examines evidence concerning cognitive function, potential neuroprotective effects against beta-amyloid injury, non-cognitive symptoms (such as depression, anxiety, irritability, aggression, and apathy), and sleep architecture.
What was found
The abstract reports no numerical data, effect estimates, sample sizes, or statistical metrics. It describes qualitative claims that choline alphoscerate has established efficacy for cognitive symptoms in MCI and dementia, with emerging evidence suggesting neuroprotective properties and benefits for non-cognitive symptoms and sleep.
Why it matters
This review outlines the clinical rationale and emerging indications for choline alphoscerate as a potential multifaceted intervention for mild cognitive impairment.
Limits
The paper is a narrative review lacking a systematic search protocol, meta-analytic pooling, or formal risk-of-bias assessment. No primary empirical data or specific study details are provided in the abstract.
Cited by
- context Alpha-GPC improves REM sleep duration.